Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,301 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions: CNS Stimulant, Placebo, CNS Stimulant open label first phase; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 7 Years to 12 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar
Interventions: Computer-Augmented Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Osteopathic Manipulation, Placebo; Other
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: Interstitial Lung Diseases
Interventions: Hyperpolarized 129Xe; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Interventions: Fitbit, Douglas Bag, Periflux 6000 EPOS, BIOPAC, Flowmet, NIRS; Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 78 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer
Interventions: DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry; Genetic
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Valganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 38
States / cities: Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more

Conditions: Chronic Pain
Interventions: Group cognitive behavioral therapy, Pain education; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anxiety Disorder of Childhood, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder
Interventions: Supportive Parenting for Anxious Childhood Emotions, Parent Educational Support, Cognitive-Behavioral Therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Septic Shock, Ascorbic Acid Deficiency
Interventions: Intravenous Ascorbic Acid; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions: Single Agent Asciminib, Low TKI, Elective Free Treatment; Drug · Combination Product · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Vitamin D Status
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV, Sleep, Smoking Cessation, Cardiovascular Diseases
Interventions: Varenicline, Smoking Cessation Counseling, Health Approach 1 to Reduce Smoking, Health Approach 2 to Reduce Smoking; Drug · Behavioral · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Tucson, Arizona

Conditions: Chronic Low Back Pain, Back Pain
Interventions: Real Acupuncture with Electrical Stimulation, Simulated Acupuncture with Electrical Stimulation; Other
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Interventions: Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more

Conditions: Aspergillosis, Candidemia
Interventions: anidulafungin and voriconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Seborrheic Dermatitis
Interventions: Ruxolitinib 1.5% Cream; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Hepatitis, Safety and Tolerability
Interventions: HEPLISAV-B; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Kidney Injury
Interventions: recAP, Placebo; Biological · Other
Lead sponsor: AM-Pharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Tampa, Florida • Idaho Falls, Idaho + 3 more

Search by objective public record fields.

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

Novel Neural Circuit Biomarkers of Major Depression Response to CCBT

Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)

Biomarkers of the Response to Osteopathic Manipulation

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain

Voriconazole to Prevent Systemic Fungal Infections in Children

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment

Wellness Intervention for Smoking and HIV

Predicting Analgesic Response to Acupuncture: A Practical Approach

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Ruxolitinib in Seborrheic Dermatitis

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI